TipRanks
Ascendis Pharma (ASND)
NASDAQ:ASND
US Market
ASND
Ascendis Pharma
RESEARCH TOOLSreports
Want to see ASND full AI Analyst Report?

Ascendis Pharma (ASND) Stock Forecast & Price Target

777 Followers
See the Price Targets and Ratings of:

ASND Analyst Ratings

Strong Buy
19Ratings
Strong Buy
19 Buy
0 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Ascendis
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$315.41
▲(26.04% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $315.41 with a high forecast of $360.00 and a low forecast of $269.00. The average price target represents a 26.04% change from the last price of $250.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"200":"$200","361":"$361","240.25":"$240.3","280.5":"$280.5","320.75":"$320.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":360,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$360.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":315.4117647058823,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$315.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":269,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$269.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[200,240.25,280.5,320.75,361],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,227.31,237.5169230769231,247.72384615384615,257.9307692307692,268.1376923076923,278.3446153846154,288.5515384615385,298.7584615384616,308.9653846153846,319.1723076923077,329.3792307692308,339.5861538461538,349.7930769230769,{"y":360,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,227.31,234.08705882352942,240.86411764705883,247.64117647058822,254.41823529411764,261.19529411764705,267.97235294117644,274.7494117647059,281.52647058823527,288.30352941176466,295.0805882352941,301.8576470588235,308.63470588235293,{"y":315.4117647058823,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,227.31,230.5169230769231,233.72384615384615,236.93076923076924,240.1376923076923,243.3446153846154,246.55153846153846,249.75846153846155,252.9653846153846,256.1723076923077,259.3792307692308,262.5861538461538,265.7930769230769,{"y":269,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":204.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.59,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.93,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.82,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":267.79,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260.25,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.31,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$360.00Average Price Target$315.41Lowest Price Target$269.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on ASND
Joon Lee
UBS
UBS
$307→$269
Buy
7.49%
Upside
Reiterated
10/16/26
Ascendis Pharma (ASND) Receives a New Rating from a Top Analyst
Morgan Stanley Analyst forecast on ASND
Maxwell Skor
Morgan Stanley
Morgan Stanley
$273
Buy
9.09%
Upside
Assigned
10/12/26
Morgan Stanley Releases a Buy Rating on Ascendis Pharma (ASND)
J.P. Morgan Analyst forecast on ASND
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
10/10/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Argenx Se (NASDAQ: ARGX) and Hinge Health, Inc. Class A (NYSE: HNGE)
Bank of America Securities Analyst forecast on ASND
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
10/09/26
Ascendis Pharma: Strong Commercial Momentum Across Yorvipath, Yuviwel, and Skytrofa Drives Buy Rating with Unchanged $304 Price Target
RBC Capital Analyst forecast on ASND
Luca Issi
RBC Capital
RBC Capital
$290
Buy
15.88%
Upside
Reiterated
10/08/26
RBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Barclays Analyst forecast on ASND
Eliana Merle
Barclays
Barclays
$329
Buy
31.47%
Upside
Reiterated
09/30/26
Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Cantor Fitzgerald Analyst forecast on ASND
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
$300
Buy
19.88%
Upside
Reiterated
09/25/26
Cantor Fitzgerald Remains a Buy on Ascendis Pharma (ASND)
H.C. Wainwright Analyst forecast on ASND
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$344
Buy
37.46%
Upside
Reiterated
09/16/26
Ascendis Pharma: Buy Rating Reaffirmed as Analyst Maintains $344 12‑Month Price Target Amid Strategic Upside From TransCon Assets
Wedbush Analyst forecast on ASND
Yun Zhong
Wedbush
Wedbush
$327
Buy
30.67%
Upside
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ascendis Pharma (NASDAQ: ASND) and Charles River Labs (NYSE: CRL)
Raymond James Analyst forecast on ASND
Martin Auster
Raymond James
Raymond James
$287
Buy
14.69%
Upside
Reiterated
09/15/26
Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond JamesAscendis Pharma downgraded to Outperform from Strong Buy at Raymond James
BMO Capital Analyst forecast on ASND
David Lebowitz
BMO Capital
BMO Capital
$319
Buy
27.47%
Upside
Reiterated
09/14/26
Ascendis Pharma: Buy Rating Reaffirmed as Durable Franchise, New Launches, and $400M Buyback Support Unchanged $319 Price Target
Oppenheimer Analyst forecast on ASND
Leland Gershell
Oppenheimer
Oppenheimer
$304→$312
Buy
24.68%
Upside
Reiterated
09/02/26
Oppenheimer Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$326
Buy
30.27%
Upside
Reiterated
09/01/26
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)
Jefferies Analyst forecast on ASND
Faisal Khurshid
Jefferies
Jefferies
$333→$330
Buy
31.87%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on ASND
Derek Archila
Wells Fargo
Wells Fargo
$326
Buy
30.27%
Upside
Reiterated
08/14/26
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on ASND
Joon Lee
UBS
UBS
$307→$269
Buy
7.49%
Upside
Reiterated
10/16/26
Ascendis Pharma (ASND) Receives a New Rating from a Top Analyst
Morgan Stanley Analyst forecast on ASND
Maxwell Skor
Morgan Stanley
Morgan Stanley
$273
Buy
9.09%
Upside
Assigned
10/12/26
Morgan Stanley Releases a Buy Rating on Ascendis Pharma (ASND)
J.P. Morgan Analyst forecast on ASND
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
10/10/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Argenx Se (NASDAQ: ARGX) and Hinge Health, Inc. Class A (NYSE: HNGE)
Bank of America Securities Analyst forecast on ASND
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
10/09/26
Ascendis Pharma: Strong Commercial Momentum Across Yorvipath, Yuviwel, and Skytrofa Drives Buy Rating with Unchanged $304 Price Target
RBC Capital Analyst forecast on ASND
Luca Issi
RBC Capital
RBC Capital
$290
Buy
15.88%
Upside
Reiterated
10/08/26
RBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Barclays Analyst forecast on ASND
Eliana Merle
Barclays
Barclays
$329
Buy
31.47%
Upside
Reiterated
09/30/26
Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Cantor Fitzgerald Analyst forecast on ASND
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
$300
Buy
19.88%
Upside
Reiterated
09/25/26
Cantor Fitzgerald Remains a Buy on Ascendis Pharma (ASND)
H.C. Wainwright Analyst forecast on ASND
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$344
Buy
37.46%
Upside
Reiterated
09/16/26
Ascendis Pharma: Buy Rating Reaffirmed as Analyst Maintains $344 12‑Month Price Target Amid Strategic Upside From TransCon Assets
Wedbush Analyst forecast on ASND
Yun Zhong
Wedbush
Wedbush
$327
Buy
30.67%
Upside
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ascendis Pharma (NASDAQ: ASND) and Charles River Labs (NYSE: CRL)
Raymond James Analyst forecast on ASND
Martin Auster
Raymond James
Raymond James
$287
Buy
14.69%
Upside
Reiterated
09/15/26
Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond JamesAscendis Pharma downgraded to Outperform from Strong Buy at Raymond James
BMO Capital Analyst forecast on ASND
David Lebowitz
BMO Capital
BMO Capital
$319
Buy
27.47%
Upside
Reiterated
09/14/26
Ascendis Pharma: Buy Rating Reaffirmed as Durable Franchise, New Launches, and $400M Buyback Support Unchanged $319 Price Target
Oppenheimer Analyst forecast on ASND
Leland Gershell
Oppenheimer
Oppenheimer
$304→$312
Buy
24.68%
Upside
Reiterated
09/02/26
Oppenheimer Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$326
Buy
30.27%
Upside
Reiterated
09/01/26
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)
Jefferies Analyst forecast on ASND
Faisal Khurshid
Jefferies
Jefferies
$333→$330
Buy
31.87%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on ASND
Derek Archila
Wells Fargo
Wells Fargo
$326
Buy
30.27%
Upside
Reiterated
08/14/26
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

3 Months
Yaron WerberTD Cowen
Success Rate
15/17 ratings generated profit
88%
Average Return
+8.26%
Copying Yaron Werber's trades and holding each position for 3 Months would result in 88.24% of your transactions generating a profit, with an average return of +8.26% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
23/25 ratings generated profit
92%
Average Return
+39.19%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 92.00% of your transactions generating a profit, with an average return of +39.19% per trade.
2 Years
Joseph SchwartzLeerink Partners
Success Rate
25/25 ratings generated profit
100%
Average Return
+65.01%
Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +65.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
0
0
0
0
Buy
26
27
37
47
46
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
27
37
47
46
In the current month, ASND has received 46 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 315.41.
Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is $0.90 with a range of $0.47 to $1.25. The previous quarter’s EPS was $3.18. ASND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.
Next quarter’s earnings estimate for ASND is $0.90 with a range of $0.47 to $1.25. The previous quarter’s EPS was $3.18. ASND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $407.97M with a range of $354.31M to $455.47M. The previous quarter’s sales results were $394.49M. ASND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.
Next quarter’s sales forecast for ASND is $407.97M with a range of $354.31M to $455.47M. The previous quarter’s sales results were $394.49M. ASND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 315.41.
    What is ASND’s upside potential, based on the analysts’ average price target?
    Ascendis Pharma has 26.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ASND a Buy, Sell or Hold?
          Ascendis Pharma has a consensus rating of Strong Buy which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ascendis Pharma’s price target?
            The average price target for Ascendis Pharma is 315.41. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $360.00 ,the lowest forecast is $269.00. The average price target represents 26.04% Increase from the current price of $250.25.
              What do analysts say about Ascendis Pharma?
              Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of ASND?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.